Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ampakine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Department of Defense
Deal Size : $1.8 million
Deal Type : Funding
RespireRx Pharmaceuticals Receives DOD Award for Phase 2 Study on CX1739 in Spinal Injury
Details : RespireRx intends to use the net proceeds to fund phase 2 clinical study of CX1739, its Lead AMPAkine, to improve bladder function in patients with spinal cord injury.
Product Name : CX1739
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : Ampakine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Department of Defense
Deal Size : $1.8 million
Deal Type : Funding
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RespireRx Reports Preclinical Pain Relief for Non-Opioid Lead GABAkine Product
Details : KRM-II-81 is an orally bioavailable imidazodiazepines that acts as a GABA-A receptor potentiator (GABAkine). It is being developed for the treatment of pain.
Product Name : KRM-II-81
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2024
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dronabinol, delta-9-THC, is a synthetic version of the naturally occurring substance in the cannabis plant. Drug is an endocannabinoid CB1 and CB2 receptor agonist which is being developed for the treatment of Obstructive sleep apnea.
Product Name : ResolutionRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : ResolutionRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, ResolutionRx will use and exploit the Licensed IP associated with new dronabinol formulations initially to be developed for the treatment of obstructive sleep apnea.
Product Name : ResolutionRx
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 08, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : ResolutionRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ampakine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : University College London
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.
Product Name : CX1739
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : Ampakine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : University College London
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KRM-II-81 analogs enhances the GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
Product Name : KRM-II-81
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The compounds described in these articles were efficacious as anticonvulsants and the most characterized of these, KRM-II-81, KPP-III-34, displayed robust activity in more advanced anti-seizure models. All compounds were effective without producing sedat...
Product Name : KRM-II-81
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : University Of Illinois Chicago
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : D9-THC (dronabinol, D9-tetrahydrocannabinol) is an oral capsule drug product that is being tested for clinical efficacy in patients with obstructive sleep apnea (OSA).
Product Name : ResolutionRx
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : University Of Illinois Chicago
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RespireRx’s ResolutionRx business unit is developing dronabinol, ∆-9-THC, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA.
Product Name : ResolutionRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CX717
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : After having shown positive activity in animal models of ADHD, CX717, lead AMPAkines, demonstrated statistically significant improvement of symptoms observed in a Phase 2 human clinical trial in adult patients with ADHD.
Product Name : CX717
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : CX717
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable